TriangleHEALTH PROFESSIONAL · SOURCE READING
Targeted therapy with TKIs
Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 13, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Relapsed CML / Treatment Options for Relapsed CML
In case of treatment failure or suboptimal response, patients should undergo BCR::ABL1 kinase domain mutation analysis to help guide therapy with the newer TKIs or with allogeneic transplant.[2,3]
Variants in the tyrosine kinase domain can confer resistance to imatinib mesylate. Alternative TKIs such as dasatinib, nilotinib, or bosutinib, higher doses of imatinib mesylate, and allogeneic stem cell transplant (SCT) have been studied in this setting.[4-16] In particular, the T315I variant marks resistance to imatinib, dasatinib, nilotinib, and bosutinib.
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice